FDA Grants AP Status for Azelastine Hydrochloride and Fluticasone Propionate
The FDA has granted Abbreviated Approval (AP) status for ANDA208111, a combination of Azelastine Hydrochloride and Fluticasone Propionate.
Therapeutic Area
Therapeutic area intelligence for Nasal Spray with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.